{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:19:28Z","timestamp":1782980368202,"version":"3.54.5"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1124\/dmd.123.001466","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T19:25:27Z","timestamp":1702063527000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-2332","authenticated-orcid":false,"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Drabison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-6690","authenticated-orcid":false,"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Eisenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9806-7734","authenticated-orcid":false,"given":"Shuiying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001466_bib1","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1038\/s41598-017-15033-0","article-title":"Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology","volume":"7","author":"Abe","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.123.001466_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1124\/dmd.123.001466_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clinthera.2015.10.017","article-title":"Severe vincristine-induced neuropathic pain in a CYP3A5 nonexpressor with reduced CYP3A4\/5 activity: case study","volume":"38","author":"Bosilkovska","year":"2016","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.123.001466_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1124\/dmd.123.001466_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2018.09.029","article-title":"Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models","volume":"840","author":"Chiorazzi","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib6","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2003.11.031","article-title":"Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia","volume":"21","author":"Den Boer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.123.001466_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/jpet.106.118471","article-title":"Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes","volume":"321","author":"Dennison","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001466_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1124\/dmd.106.009902","article-title":"Selective metabolism of vincristine in vitro by CYP3A5","volume":"34","author":"Dennison","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001466_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1124\/jpet.108.139998","article-title":"Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes","volume":"327","author":"Dennison","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001466_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"key":"10.1124\/dmd.123.001466_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.123.001466_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/2767-9764.CRC-21-0076","article-title":"Intentional modulation of ibrutinib pharmacokinetics through CYP3A inhibition","volume":"1","author":"Eisenmann","year":"2021","journal-title":"Cancer Res Commun"},{"key":"10.1124\/dmd.123.001466_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1439-0507.2009.01820.x","article-title":"Clinically relevant drug interactions of current antifungal agents","volume":"53","author":"Gubbins","year":"2010","journal-title":"Mycoses"},{"key":"10.1124\/dmd.123.001466_bib14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-010-1541-4","article-title":"Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases","volume":"68","author":"Guilhaumou","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109559","article-title":"Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro","volume":"345","author":"Han","year":"2021","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.123.001466_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1890\/0012-9658(1999)080[1150:TMAORR]2.0.CO;2","article-title":"The meta-analysis of response ratios in experimental ecology","volume":"80","author":"Hedges","year":"1999","journal-title":"Ecology"},{"key":"10.1124\/dmd.123.001466_bib17","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1172\/JCI136796","article-title":"Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice","volume":"130","author":"Huang","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.123.001466_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122591","article-title":"Rapid quantification of vincristine in mouse plasma using ESI-LC-MS\/MS: application to pharmacokinetic studies","volume":"1168","author":"Jin","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.123.001466_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.123.001466_bib20","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/NCC.0b013e318299ad23","article-title":"Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"36","author":"Lavoie Smith","year":"2013","journal-title":"Cancer Nurs"},{"key":"10.1124\/dmd.123.001466_bib21","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio Protoc"},{"key":"10.1124\/dmd.123.001466_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.123.001466_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: a mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"key":"10.1124\/dmd.123.001466_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164646","article-title":"Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1124\/dmd.123.001466_bib25","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.123.001466_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-019-03884-5","article-title":"Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review","volume":"84","author":"Madsen","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","article-title":"Drug-drug-gene interactions and adverse drug reactions","volume":"20","author":"Malki","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.123.001466_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1440-1754.2011.02103.x","article-title":"Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach","volume":"47","author":"Moore","year":"2011","journal-title":"J Paediatr Child Health"},{"key":"10.1124\/dmd.123.001466_bib29","first-page":"2416","article-title":"Vincristine-induced peripheral neuropathy in pediatric cancer patients","volume":"6","author":"Mora","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1124\/dmd.123.001466_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1439-0507.2011.02158.x","article-title":"Adverse interactions between antifungal azoles and vincristine: review and analysis of cases","volume":"55","author":"Moriyama","year":"2012","journal-title":"Mycoses"},{"key":"10.1124\/dmd.123.001466_bib31","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1097\/MPH.0000000000001220","article-title":"Vincristine associated neuropathy with antifungal usage: a Kaiser Northern California experience","volume":"40","author":"Nikanjam","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1124\/dmd.123.001466_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00280-021-04302-5","article-title":"Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors","volume":"88","author":"Pilla Reddy","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/17425255.2021.1855141","article-title":"Genetic factors influencing the development of vincristine-induced neurotoxicity","volume":"17","author":"Pozzi","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001466_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.123.001466_bib35","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","article-title":"CYP3A5 genetic polymorphisms in different ethnic populations","volume":"33","author":"Roy","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001466_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214553143","article-title":"The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia","volume":"22","author":"Sims","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1124\/dmd.123.001466_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26854","article-title":"CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer","volume":"65","author":"Skiles","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.123.001466_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26525","article-title":"Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia","volume":"64","author":"Smitherman","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1124\/dmd.123.001466_bib39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/cts.12915","article-title":"Role for drug transporters in chemotherapy-induced peripheral neuropathy","volume":"14","author":"Stage","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001466_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0091270010367428","article-title":"Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants","volume":"51","author":"Tanaka","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib41","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/cancers14030612","article-title":"Pharmacogenomics of vincristine-induced peripheral neuropathy in children with cancer: a systematic review and meta-analysis","volume":"14","author":"Uittenboogaard","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/dmd.123.001466_bib42","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3390\/cancers12071789","article-title":"Population pharmacokinetics of vincristine related to infusion duration and peripheral neuropathy in pediatric oncology patients","volume":"12","author":"van de Velde","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1124\/dmd.123.001466_bib43","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.3390\/cancers14143510","article-title":"Genetic polymorphisms associated with vincristine pharmacokinetics and vincristine-induced peripheral neuropathy in pediatric oncology patients","volume":"14","author":"van de Velde","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/dmd.123.001466_bib44","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia","volume":"66","author":"van Schie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.123.001466_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001466_bib46","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/neuonc\/noq056","article-title":"Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors","volume":"12","author":"Wang","year":"2010","journal-title":"Neuro-oncol"},{"key":"10.1124\/dmd.123.001466_bib47","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcph.434","article-title":"Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam","volume":"55","author":"Zhang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001466_bib48","first-page":"5121","article-title":"Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions","volume":"53","author":"Zhou-Pan","year":"1993","journal-title":"Cancer Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:06:51Z","timestamp":1739956011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624011188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0090955624011188"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001466","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}